These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
5. Treatment of pruritus with topically applied opiate receptor antagonist. Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241 [TBL] [Abstract][Full Text] [Related]
6. Varying clinical contexts for administering naltrexone. Hurzeler M; Gerwirtz D; Kleber H NIDA Res Monogr; 1976 Sep; (9):48-66. PubMed ID: 794721 [No Abstract] [Full Text] [Related]
7. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
8. [Ultra-rapid detoxification of opiate dependent patients: review of the literature, critiques and proposition for an experimental protocol]. Fontaine E; Godfroid IO; Guillaume R Encephale; 2001; 27(2):187-93. PubMed ID: 11407272 [TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Guardia J; Caso C; Arias F; Gual A; Sanahuja J; Ramírez M; Mengual I; Gonzalvo B; Segura L; Trujols J; Casas M Alcohol Clin Exp Res; 2002 Sep; 26(9):1381-7. PubMed ID: 12351933 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
11. Naltrexone in autistic children: a double-blind and placebo-controlled study. Campbell M; Anderson LT; Small AM; Locascio JJ; Lynch NS; Choroco MC Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621 [TBL] [Abstract][Full Text] [Related]
12. Operant analysis of human heroin self-administration and the effects of naltrexone. Mello NK; Mendelson JH; Kuehnle JC; Sellers MS J Pharmacol Exp Ther; 1981 Jan; 216(1):45-54. PubMed ID: 7452507 [TBL] [Abstract][Full Text] [Related]
13. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401 [TBL] [Abstract][Full Text] [Related]
14. Short-term effects of naltrexone in 155 heroin ex-addicts. Volavka J; Resnick RB; Kestenbaum RS; Freedman AM Biol Psychiatry; 1976 Dec; 11(6):679-85. PubMed ID: 999987 [TBL] [Abstract][Full Text] [Related]
15. Clinical experience with naltrexone in suburban opioid addicts. Tennant FS; Rawson RA; Cohen AJ; Mann A J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]